Requests the La. Department of Health to study the scheduling of Mitragyna speciosa (kratom) as a controlled dangerous substance
The bill aims primarily at assessing the regulatory status of kratom in Louisiana. While it does not impose any immediate legal changes, the outcomes of the requested study could eventually lead to significant shifts in how kratom is classified and regulated within the state. If kratom were to be scheduled as a controlled substance, it would impact not only its legality but also its availability to consumers, potentially affecting local businesses that currently sell kratom products.
House Resolution 177 urges the Louisiana Department of Health to study the scheduling of Mitragyna speciosa, commonly known as kratom, as a controlled dangerous substance. The resolution highlights the risks associated with kratom, including warnings from the Food and Drug Administration (FDA) against its use due to concerns of toxicity and potential harm. The resolution calls for a detailed examination and a report with findings and recommendations, which is expected to be delivered to the appropriate legislative committee before the next regular session of the Louisiana Legislature in 2019.
The sentiment regarding HR177 appears to be supportive among legislators who recognize the need to evaluate the safety and legality of kratom. However, there could be contention among public health advocates and consumers who regard kratom as a helpful alternative for various conditions. The discussions may also reflect broader debates concerning government regulation of natural substances and the balance between public health and personal choice.
One major point of contention surrounding HR177 relates to the classification of kratom. Some advocates argue that kratom has beneficial uses, while opponents raise serious concerns about its safety and potential for abuse. The outcome of the study requested by HR177 could determine whether kratom is classified in a way that restricts its access for consumers who may view it as a therapeutic option.